Evoke Pharma (NASDAQ:EVOK) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened

Evoke Pharma, Inc. (NASDAQ:EVOK) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $4.64 and traded as low as $2.66. Evoke Pharma shares last traded at $2.79, with a volume of 11,492 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Evoke Pharma in a research report on Friday. They issued a “sell” rating for the company.

Evoke Pharma Stock Performance

The company has a 50-day moving average price of $4.25 and a two-hundred day moving average price of $4.63. The stock has a market cap of $4.17 million, a P/E ratio of -0.25 and a beta of 0.12.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The firm had revenue of $3.31 million for the quarter, compared to the consensus estimate of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Institutional Trading of Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC lifted its holdings in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after buying an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.